Miglustat / OGT 918 in the Treatment of Cystic Fibrosis
Status:
Terminated
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
Cystic fibrosis is a genetic disease caused by mutation of the cystic fibrosis transmembrane
conductance regulator (CFTR). The purpose of the study is to investigate the effects of
miglustat on CFTR function in cystic fibrosis patients.